Senescent cells — those locked in permanent cell-cycle arrest and secreting a pro-inflammatory cocktail called the SASP (senescence-associated secretory phenotype) — accumulate across tissues with age, driving cardiovascular disease, neurodegeneration, fibrosis, and metabolic dysfunction. Early clinical trials of senotherapeutics — drugs that either selectively kill senescent cells (senolytics) or suppress their harmful secretions (senomorphics) — are now showing preliminary functional improvements in idiopathic pulmonary fibrosis and diabetic kidney disease, two conditions with notoriously limited treatment options.
This review consolidates a field that has accelerated sharply since the 2015 landmark mouse studies by the Kirkland group demonstrating that clearing senescent cells extended healthspan. What's notable here is the clinical signal: most senolytic work has been preclinical, so any functional benefit in human trials — even preliminary — represents meaningful translational progress. The senolytic combination of dasatinib plus quercetin and navitoclax remain the most-studied agents. However, the field faces genuine obstacles the author candidly acknowledges: senescence is not a uniform state but a heterogeneous spectrum varying by tissue, trigger, and time; biomarkers like p16INK4a and p21 lack tissue specificity; and long-term safety of eliminating cells that normally suppress tumors is unresolved. This is a confirmatory and well-framed synthesis rather than a paradigm shift, but it accurately maps the distance between promising biology and actionable human medicine — a gap that remains substantial.
